Top Markets
#1 Verus Coin Verus Coin +22.44%
#2 Ontology Gas Ontology Gas +19.53%
#3 Status Status +17.90%
#4 ETHGas ETHGas +15.70%
#5 Geodnet Geodnet +13.21%
#6 Derive Derive +12.82%
#7 Curve DAO Curve DAO +11.62%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +9.94%
#9 Anvil Anvil +9.76%
#10 The Black Bull The Black Bull +9.10%
Coin of the day
Verus Coin Verus Coin
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Carna Biosciences, Inc. Carna Biosciences, Inc.

Carna Biosciences, Inc.

4572
Classement en actions #25406
Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a... Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a clinical-stage biopharmaceutical company. Its core focus is on discovering and developing novel drug treatments for significant unmet medical needs, particularly within the Japanese market. In addition to its drug discovery efforts, Carna Biosciences offers an array of specialized research tools. These comprise diverse kinase proteins, their corresponding substrates, comprehensive kinase protein assay kits, stable cell lines, and biotinylated kinases, which are instrumental in investigating kinase-molecule interactions. The company also delivers a wide spectrum of scientific services. These services span from in-depth profiling and various cell-based kinase assays, including NanoBRET TE and ClariCELL intracellular assays, to protein detection and interaction analysis, live-cell kinase assays, crystallization, and weak affinity chromatography. Furthermore, they provide tyrosine kinase cell-based assay services and custom synthesis of ultra-pure proteins specifically for crystallography. Its therapeutic pipeline highlights several key investigational compounds. AS-0141, an orally administered small molecule designed to inhibit CDC7 kinase, is currently undergoing preclinical studies for cancer treatment. Another small molecule, AS-0871, is advancing through Phase 1 clinical trials for inflammatory and immune disorders. Moreover, AS-1763, an orally bioavailable, non-covalent inhibitor, is in preclinical assessment for chronic lymphocytic leukemia and other B-cell malignancies. Strategic collaborations have been established with leading pharmaceutical organizations, including Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals.
Prix de l'action
$2.62
Capitalisation boursière
$50.19M
Changement (1 jour)
-1.47%
Changement (1 an)
77.21%
Pays
JP
Échange Carna Biosciences, Inc. (4572)

Catégorie

Healthcare
Marge opérationnelle de Carna Biosciences, Inc. (4572)
Marge opérationnelle au 2026 TTM : 0.00%
Selon les derniers rapports financiers et le cours de l'action de Carna Biosciences, Inc., la marge opérationnelle actuelle (TTM) est de 0.00%. À la fin de 2026, elle était de 0.00%.
Historique de la marge opérationnelle pour Carna Biosciences, Inc. de 2026 à 2026
Marge opérationnelle à la fin de chaque année
Année Marge opérationnelle Changez
Pas assez de données pour les dates fournies.
Marge opérationnelle pour des entreprises similaires ou concurrentes
Entreprise Marge opérationnelle Différence de Marge Opérationnelle Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
Qu'est-ce que la Marge opérationnelle d'une entreprise ?
La Marge opérationnelle est un indicateur clé pour évaluer la rentabilité d'une entreprise. Une marge d'exploitation plus élevée est généralement préférable car elle montre qu'une entreprise peut vendre ses produits ou services bien au-dessus de leurs coûts de production. Elle se calcule en divisant les bénéfices par le chiffre d'affaires.